Bladder cancer biomarker proteins

US11536724B2 · kind B2 · utility

Assignees

• POLYQUANT GMBH · DE
• COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · FR
• BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS · GR
• LUXEMBOURG INSTITUTE OF HEALTH · LU
• INSTITUT CURIE · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III, CNIO

Inventors

• Jerome Garin · Paris, FR
• Christophe Masselon · Paris, FR
• Antonia Vlahou · Athens, GR
• Manousos Makrydakis · Athens, GR
• Ieronimos Zoidakis · Athens, GR
• Bruno Domon · Zürich, CH
• Elodie Duriez · Arlon, BE
• Aurelie Kamoun · Paris, FR
• Francois Radvanyi · Fontenay-aux-Roses, FR
• Yves Allory · Paris, FR
• Nuria MALATS RIERA · Madrid, ES
• Mirari Marquez Cid · Madrid, ES
• Magali Court · Paris, FR

Key dates

• Filing date: Dec 23, 2016
• Grant date: Dec 27, 2022
• Expiry date: Dec 21, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/7028
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis, to an artificial protein comprising signature peptides representing at least 10 proteins and to a nucleic acid construct encoding for such an artificial protein. The invention further relates to a collection of at least 10 proteins for use in cancer diagnosis and/or prognosis. Additionally, the invention relates to a method for cancer diagnosis and/or prognosis comprising the step of analyzing at least 10 proteins in a urine sample of a subject. Finally, the invention relates to an immunoassay product comprising antibodies for detecting at least 10 proteins.